Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MEDICAID COST SAVINGS THROUGH DRUG MANUFACTURER REBATES

Executive Summary

State Medicaid agencies can achieve savings by obtaining price rebates directly from manufacturers, under a proposal floated by Sen. Pryor (D-Ark.) on March 20. Pre-negotiated discounts are based on a percentage of products' wholesale acquisition cost, according to the payment plan, excerpted below from the legislation. Rebates from manufacturers: Each state medical Assistance agency shall periodically obtain a rebate from each manufacturer with whom negotiations were successful, in an amount calculated as the product of - * the documented number of tablets or other dosage form units of the manufacturer's prescription drug which has been dispensed to qualified beneficiaries of the state medical assistance program, and * the difference between the negotiated per tablet or other dosage unit price and the per tablet or per unit wholesale acquisition price. State reliance on National Pharmacy and Therapeutics Committee Determinations: The state medical assistance plan shall (except states grandfathered under Section 5(a)(5)) incorporate by reference the determinations of the National Pharmacy and Therapeutics Committee with respect to which prescription drugs are - * medically accepted for a given therapeutic indication, and * equally safe and effective therapeutic alternatives. Access to drug therapies guaranteed: The State medical assistance plan shall provide that at least one drug in every group of equally safe and effective therapeutic alternatives is covered and reimbursable as a preferred drug.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017163

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel